Operator: Welcome to the Iovance Biotherapeutics Third Quarter and Year-to-Date 2025 Conference Call. My name is Daniel, and I will be your operator for today’s call. [Operator Instructions] Please note that this conference call is being recorded. I will now turn the call over to Sara Pellegrino, Senior Vice President, Investor Relations and Corporate Communications at Iovance. Sara, you may begin.
—
**Sara Pellegrino**
Senior Vice President of Investor Relations & Corporate Communications
Thank you, operator. Good morning, and welcome to the Iovance webcast to discuss our business achievements, pipeline milestones, and third quarter 2025 results.
Members of our executive leadership team speaking on today’s call include:
– Dr. Fred Vogt, Interim CEO and President
– Corleen Roche, Chief Financial Officer
– Dan Kirby, Chief Commercial Officer
– Dr. Igor Bilinsky, Chief Operating Officer
– Dr. Friedrich Finckenstein, Chief Medical Officer
During the question-and-answer session, we will also welcome:
– Dr. Raj Puri and Mark Theoret from our Regulatory Affairs executive leadership team
– Dr. Brian Gastman, Executive Vice President of Translational Medicine and Research
This morning, we issued a press release that is available on our corporate website.
https://seekingalpha.com/article/4839568-iovance-biotherapeutics-inc-iova-q3-2025-earnings-call-transcript?source=feed_all_articles